| NCT05845671 | University of Colorado, Denver|Janssen Research & Development, LLC | Lung Cancer|Non Small Cell Lung Cancer | 2023-07-17 | PHASE1|PHASE2 |
| NCT05117931 | Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals | Esophagogastric Cancer | 2021-12-02 | PHASE2 |
| NCT04487080 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2020-09-30 | PHASE3 |
| NCT06116682 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Lung Non-Small Cell Carcinoma | 2024-11-19 | PHASE2 |
| NCT04988295 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2021-11-17 | PHASE3 |
| NCT06532032 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2024-07-23 | PHASE1|PHASE2 |
| NCT06855849 | Yonsei University | RAS+BRAF Wild-type Advanced Colorectal Cancer Patients | 2025-05 | PHASE2 |
| NCT05601973 | ETOP IBCSG Partners Foundation|Janssen Pharmaceuticals | Non Small Cell Lung Cancer | 2023-03-27 | PHASE2 |
| NCT05379595 | Janssen Research & Development, LLC | Advanced or Metastatic Colorectal Cancer | 2022-07-29 | PHASE1|PHASE2 |
| NCT06750094 | Janssen Research & Development, LLC | Colorectal Neoplasms | 2024-12-12 | PHASE3 |
| NCT04077463 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2019-09-04 | PHASE1 |
| NCT06662786 | Janssen Research & Development, LLC | Colorectal Neoplasms | 2024-10-18 | PHASE3 |
| NCT04599712 | Janssen Research & Development, LLC | Metastatic Non-Small Cell Lung Cancer | | |
| NCT05388669 | Janssen Research & Development, LLC | Advanced or Metastatic Non-small Cell Lung Cancer | 2022-08-05 | PHASE3 |
| NCT07062354 | SWOG Cancer Research Network|Janssen Medical Affairs|SWOG Clinical Trials Partnerships, LLC | Head &Amp; Neck Cancer|Head &Amp; Neck Squamous Cell Carcinoma | 2026-03-25 | PHASE2 |
| NCT05801029 | AstraZeneca|Parexel | Non-Small Cell Lung Cancer (NSCLC) | 2023-07-18 | PHASE2 |
| NCT04538664 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2020-10-13 | PHASE3 |
| NCT06784791 | University Hospital, Essen | Lung Cancer (NSCLC) | 2024-11-06 | PHASE2 |
| NCT04965090 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC | Metastatic Non Small Cell Lung Cancer|Recurrent Non Small Cell Lung Cancer | 2021-09-30 | PHASE2 |
| NCT07227025 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2026-03-03 | PHASE1|PHASE2 |
| NCT02609776 | Janssen Research & Development, LLC | Non-Small-Cell Lung Cancer | 2016-05-24 | PHASE1 |
| NCT05074940 | Trisha Wise-Draper | Salivary Gland Cancer | 2022-08-05 | PHASE2 |
| NCT07392658 | Fondazione Ricerca Traslazionale | Metastatic NSCLC - Non-Small Cell Lung Cancer | 2025-12-02 | PHASE2 |
| NCT05908734 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2023-05-18 | PHASE1|PHASE2 |
| NCT06385080 | Janssen Research & Development, LLC | Squamous Cell Carcinoma of Head and Neck | 2024-04-22 | PHASE1|PHASE2 |
| NCT05845450 | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer|Resectable Colorectal Carcinoma | 2023-05-11 | PHASE2 |
| NCT06083857 | M.D. Anderson Cancer Center | Non-small Cell Lung Cancer | 2024-06-18 | PHASE1|PHASE2 |
| NCT06632236 | Institute of Cancer Research, United Kingdom|Royal Marsden NHS Foundation Trust|Cambridge University Hospitals NHS Foundation Trust|Janssen Pharmaceutica N.V., Belgium|Cancer Research UK|Minderoo Foundation|University of Cambridge | Malignant Primary Gliomas|Glioblastoma Multiform (Grade IV Astrocytoma)|Diffuse Hemispheric Glioma, H3 G34-Mutant|Glioblastoma Multiforme (GBM) | 2024-10-09 | PHASE1 |
| NCT03767075 | Vall d´Hebron Institute of Oncology|Roche Pharma AG|IQVIA Pty Ltd|Taisho Pharmaceutical Co., Ltd.|Janssen, LP | Advanced Solid Tumor | 2018-12-10 | PHASE2 |
| NCT07507188 | Yonsei University | Non Small Cell Lung Cancer | 2026-04-06 | PHASE2 |
| NCT06816992 | ORIC Pharmaceuticals|Janssen Research and Development LLC | Solid Tumors|EGFR Exon 20 Insertion Mutations|NSCLC|EGFR-mutated NSCLC | 2025-02-27 | PHASE1 |
| NCT04945733 | Janssen Pharmaceutical K.K. | Stomach Neoplasms|Esophageal Neoplasms | 2021-08-30 | PHASE2 |
| NCT05299125 | Latin American Cooperative Oncology Group|Janssen, LP | Metastatic Non-small Cell Lung Cancers | 2023-05-24 | PHASE2 |
| NCT06120140 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2024-02-16 | PHASE2 |
| NCT05663866 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2023-05-18 | PHASE2 |
| NCT06507306 | Kumquat Biosciences Inc. | Solid Tumor, Adult | 2024-06-03 | PHASE1 |
| NCT05488314 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | 2022-12-13 | PHASE1|PHASE2 |
| NCT05498428 | Janssen Research & Development, LLC | Carcinoma, Non-small-Cell Lung | 2022-11-11 | PHASE2 |
| NCT07276399 | Janssen Research & Development, LLC | Squamous Cell Carcinoma of Head and Neck | 2025-12-03 | PHASE3 |
| NCT07042295 | National Cancer Institute (NCI) | Locally Recurrent Skin Squamous Cell Carcinoma|Metastatic Skin Squamous Cell Carcinoma | 2026-03-23 | PHASE2 |